Stay updated with breaking news from Development For Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Initiated ADI-001 Phase 1 EXPAND cohort in post chimeric antigen receptor (CAR) T large B cell lymphoma (LBCL)Continuing to enroll mantle cell lymphoma (MCL) patients in ADI-001 Phase 1 studyPrioritizing ADI-270 for solid tumor applications; on track to file ADI-270 Investigational New Drug Application (IND) in 1H 2...
Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress -- Total Revenues of $23.3 Million for the First Quarter of 2021; XPOVIO® (selinexor) Net Product Sales of $21.7 Million -- -- Conditional Marketing Authorization Granted by the European Commission for NEXPOVIO® (selinexor) in Penta-Refractory Multiple Myeloma; European Decision for Expanded Multiple Myeloma Indication Expected in the Fourth Quarter of 2021 -- -- Richard Paulson Appointed Next President and Chief Executive Officer of Karyopharm -- -- Conference Call Scheduled for Today at 8:30 a.m...
Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress -- Commercial Launch of XPOVIO® (selinexor) In Expanded Multiple Myeloma Indication Fully Underway Following December 18, 2020 FDA Approval -- -- XPOVIO Net Product Sales of $20.2 Million for Fourth Quarter 2020 and $76.2 Million for the Year 2020; Total Revenues of $35.1 Million for the Fourth Quarter 2020 and $108.1 Million for the Year 2020 -- -- Positive CHMP Opinion for NEXPOVIO® (selinexor) in Penta-Refractory Multiple Myeloma Issued; European Commission Decision Expected by A...